Evidence map›Paper›PMID 24986062›Full record

Trial reportThe journals of gerontology. Series A, Biological sciences and medical sciences2015

Aging and physical function in type 2 diabetes: 8 years of an intensive lifestyle intervention.

W Jack Rejeski, George A Bray, Shyh-Huei Chen, Jeanne M Clark, Mary Evans, James O Hill, John M Jakicic, Karen C Johnson, Rebecca Neiberg, Edward H Ip and 1 more

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The journals of gerontology. Series A, Biological sciences and medical sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Late-life disability following the action for health in diabetes (Look AHEAD) trial.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Obesity and healthy aging: fat, muscle, and bone trade-offs in an era of potent weight-loss pharmacotherapy.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
    Article
  14. Observational
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

W Jack RejeskiDepartment of Health and Exercise Science, Wake Forest University, Reynolda Campus, Winston-Salem, North Carolina. rejeski@wfu.edu.
George A BrayPennington Biomedical Research Center/LSU, Baton Rouge, Louisiana.
Shyh-Huei ChenDepartment of Biostatistical Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Jeanne M ClarkDivision of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
Mary EvansNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
James O HillDepartment of Pediatrics and Medicine, University of Colorado School of Medicine, Denver.
John M JakicicDepartment of Health and Physical Activity, University of Pittsburgh, Pennsylvania.
Karen C JohnsonDepartment of Preventive Medicine, University of Tennessee Health Science Center, Memphis.
Rebecca NeibergDepartment of Biostatistical Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Edward H IpDepartment of Biostatistical Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Look AHEAD Research Group
Wake Forest University · USJohns Hopkins University · USNational Institute of Diabetes and Digestive and Kidney Diseases · USPennington Biomedical Research Center · USUniversity of Colorado Denver · USUniversity of Tennessee Health Science Center · US

Funding

UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE: BPCAUL1RR024153 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2006 to 2011
$73.9M
Look AHEAD: Action for Health in DiabetesU01DK057136 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ESPELAND, MARK ANDREW, WAGENKNECHT, LYNNE E · 1999 to 2020
$54.9M
ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI KOSMISKI, LISA A. · 1985 to 2008
$52.6M
Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI BROWN, EMERY N · 1985 to 2008
$37.4M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Wendy M Kohrt · 1995 to 2026
$32.6M
Harvard Clinical and Translational Science Center (UL1)UL1TR000170 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2012 to 2013
$31.4M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
ZOLEDRONATE VS AREDIA IN MULTIPLE MYELOMA/BREAST CANCER W /BONE DISORDERSM01RR001346 · NCRR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FERRER, ROBERT L · 1985 to 2008
$23.1M
SHOW PROJECTU01DK057154 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI NATHAN, DAVID M · 1999 to 2020
$23.1M
Look AHEAD: Action for Health DiabetesU01DK057178 · NIDDK · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI LAFERRERE, BLANDINE B · 1999 to 2020
$21.2M
Intramural NIH HHSNCATS NIH HHS UL1 TR000170NCATS NIH HHS UL1 TR001082NCATS NIH HHS UL1 TR001120NCRR NIH HHS M01RR000056NCRR NIH HHS M01RR00051NCRR NIH HHS M01RR0021140NCRR NIH HHS M01RR01066NCRR NIH HHS M01RR01346NCRR NIH HHS M01RR02719NCRR NIH HHS UL1 RR 024153NHLBI NIH HHS R18 HL076441NIA NIH HHS R21AG042761-01NIDDK NIH HHS DK046204NIDDK NIH HHS DK56990NIDDK NIH HHS DK56992NIDDK NIH HHS DK57002NIDDK NIH HHS DK57008NIDDK NIH HHS DK57078NIDDK NIH HHS DK57131NIDDK NIH HHS DK57135NIDDK NIH HHS DK57136NIDDK NIH HHS DK57149NIDDK NIH HHS DK57151NIDDK NIH HHS DK57154NIDDK NIH HHS DK57171NIDDK NIH HHS DK57177NIDDK NIH HHS DK57178NIDDK NIH HHS DK57182NIDDK NIH HHS DK57219NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK48520NIDDK NIH HHS U01 DK057149
6 · The paper itself

Abstract

backgroundCompared with adults without type 2 diabetes mellitus, those with the disease experience more limitations in their physical functioning (PF). Look AHEAD is a large multicenter trial that examined the effects of an intensive lifestyle intervention (ILI) for weight loss on cardiovascular outcomes compared with diabetes support and education (DSE). Although the current study compared treatment differences between ILI and DSE on PF, the primary goal was to examine whether this effect was moderated by age and history of cardiovascular disease at enrollment.

methodsOverweight or obese adults with type 2 diabetes mellitus (n = 5,145) were randomly assigned to either ILI or DSE. The mean (±SD) age and % females in ILI was 58.9 years (±6.9) and 59.8%; it was 58.6 years (6.8) and 59.5% in DSE. Analysis in 4,998 participants assessed the differential rates of decline in PF across a period of 8 years for the ILI and DSE groups.

resultsILI resulted in improved PF compared with DSE after 1 year (p < .0001) and was maintained across time. Within the ILI, older adults experienced greater improvements than younger adults (p < .0001). By year 2, persons in ILI with preexisting cardiovascular disease were no different in PF than in DSE participants with preexisting cardiovascular disease.

conclusionWith the exception of persons who had a history of cardiovascular disease, ILI slowed the decline in PF with type 2 diabetes mellitus despite weight regain, an effect that was stronger for older than younger participants and could translate into reductions in falls and disability.

Indexed as

Life StyleAgedAge FactorsCardiovascular DiseasesCohort StudiesDiabetes Mellitus, Type 2FemaleHumansMaleMiddle AgedMotor ActivityObesityWeight LossDiabetesFunctional performance.Obesity

Identifiers

PMID24986062
PMCPMC4351390
OpenAlexW2171118722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.